The new drug is manufactured by Sanofi SA and Regeneron Pharmaceuticals and it is named Praluent.
In the panel, 13 members voted for the drug and the remaining 3 were on the other side.
The new drug is the first in a new class of cholesterol lowering drugs that inhibit PCSK, a certain king of protein.
Many of the panelists of FDA said that they were willing to see the use of the new drug in limits for start, mainly for patients who are having genetic tendency of high cholesterol and for others at a greater risk of cardiovascular disease.
The panelists also said they also wanted to see in the current trail if the LDL lowering drug works for reducing cardiovascular risk. Following the right results, the drug may be recommended for wider use among patients.
FDA is not under compulsion to listen to the advice of panelists, but generally, the same is followed.
Repatha, another drug of the same class, which is manufactures by Amgen Inc, will be considered on Wednesday.
Reports said that the approved drugs will generate huge sales for the companies concerned. The overall annual sales can be $2.5 billion by 2020 for each drug, according to Thompson Reuter’s data.
The new development is significant for the fact that the panel discussed the use of LDL after years. Most panelists agreed that the LDL lowering approach is a good surrogate for cardiovascular benefit for statins.
Reports said that Sanofi expects to show the results of the trail by the end of 2017.
The panelists are having some concerns on how the drug will increase risk of higher blood sugar levels, but nothing is clear with regards to the risks mentioned. Other concerns were also with regards to the liver and cognition.
Praluent is meant to be given to patients by injections twice a week.